top of page

 OUR PUBLICATIONS 

2024

Robust and persistent B-cell responses following SARS-CoV-2 vaccine determine protection from SARS-CoV-2 infection.

Byrne J, Gu L, Garcia-Leon A, Gaillard CM, Saini G, Alalwan D, Tomás-Cortázar J, Kenny G, Donohue S, Reynolds B, O'Gorman T, Landay A, Doran P, Stemler J, Koehler P, Cox RJ, Olesen OF, Lelievre JD, O'Broin C, Savinelli S, Feeney ER, O'Halloran JA, Cotter A, Horgan M, Kelly C, Sadlier C, de Barra E, Cornely OA, Gautier V, Mallon PW.

Front Immunol. 2024 Sep 17;15:1445653.

2024

Low Rates of Immunity among Medical Students and Residents in the Era of the Resurgence of Measles.

Ferrari C, Somma G, Caputi V, Treglia M, Pallocci M, Cenko F, Buonomo E, Carestia M, Di Giampaolo L, Olesen OF, Coppeta L.

Pathogens. 2024 Sep 11;13(9):784.

2024

How to develop a controlled human infection model for Clostridioides difficile.

Hensen ADO, Vehreschild MJGT, Gerding DN, Krut O, Chen W, Young VB, Tzipori S, Solbach P, Gibani MM, Chiu C, de Keersmaecker SCJ, Dasyam D, Morel S, Devaster JM, Corti N, Kuijper EJ, Roestenberg M, Smits WK.

Clin Microbiol Infect. 2024 Aug 29:S1198-743X(24)00425-7.

2024

Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge.

Nkumama IN, Ogwang R, Odera D, Musasia F, Mwai K, Nyamako L, Murungi L, Tuju J, Fürle K, Rosenkranz M, Kimathi R, Njuguna P, Hamaluba M, Kapulu MC, Frank R. CHMI-SIKA study team; Osier FHA.

Immunity. 2024 Jun 11;57(6):1215-1224.e6.

2024

Perspectives of European Patient Advocacy Groups on Volunteer Registries and Vaccine Trials: VACCELERATE Survey Study.

Themistocleous S, Argyropoulos CD, Vogazianos P, Shiamakkides G, Noula E, Nearchou A, Yiallouris A, Filippou C, Stewart FA, Koniordou M, Kopsidas I, Askling HH, Vene S, Gagneux-Brunon A, Prellezo JB, Álvarez-Barco E, Salmanton-García J, Leckler J, Macken AJ, Davis RJ, Azzini AM, Armeftis C, Hellemans M, Di Marzo R, Luis C, Olesen OF, Valdenmaiier O, Jakobsen SF, Nauclér P, Launay O, Mallon P, Ochando J, van Damme P, Tacconelli E, Zaoutis T, Cornely OA, Pana ZD.

JMIR Public Health Surveill. 2024 Apr 4;10:e47241.

2024

Accelerating vaccine manufacturing development through model-based approaches: current advances and future opportunities

Ramin E, Cardillo AG, Liebers R, Schmölder J, von Lieres E, Van Molle W, Niebel B, Natalis L, Meln I, Perea-Vélez M, Clénet D, Jørgensen JB, Nilsson B, Bracewell DG, Gernaey KV.

Curr Opin Chem Eng. 2024;43:100998

2024

Ethical approval for controlled human infectious model clinical trial protocols - A workshop report.

Jamrozik E, Littler K, Meln I, Van Molle W, Morel S, Olesen OF, Rubbrecht M, Balasingam S, Neels P.

Biologicals. 2024 Feb;85:101748.

2024

Fourth Controlled Human Infection Model (CHIM) meeting, CHIM regulatory issues, May 24, 2023.

Cavaleri M, Kaslow D, Boateng E, Chen WH, Chiu C, Choy RKM, Correa-Oliveira R, Durbin A, Egesa M, Gibani M, Kapulu M, Katindi M, Olotu A, Pongsuwan P, Simuyandi M, Speder B, Talaat KR, Weller C, Wills B, Baay M, Balasingam S, Olesen OF, Neels P.

Biologicals. 2024 Feb;85:101745.

2024

Persistence of Anti-SE36 Antibodies Induced by the Malaria Vaccine Candidate BK-SE36/CpG in 5-10-Year-Old Burkinabe Children Naturally Exposed to Malaria.

Nebie I, Palacpac NMQ, Bougouma EC, Diarra A, Ouédraogo A, D'Alessio F, Houard S, Tiono AB, Cousens S, Horii T, Sirima SB.

Vaccines (Basel). 2024 Feb 6;12(2):166.

2024

Regulatory workshop on challenge strain development and GMP manufacture - A stakeholder meeting report.

Corti N, Chiu C, Cox RJ, Demont C, Devaster JM, Engelhardt OG, Gorringe A, Hassan K, Hoefnagel M, Kamerling I, Krut O, Lane C, Liebers R, Luke C, Van Molle W, Morel S, Neels P, Roestenberg M, Rubbrecht M, Klaas Smits W, Stoughton D, Talaat K, Vehreschild MJGT, Wildfire A, Meln I, Olesen OF.

Biologicals. 2024 Feb;85:101746.

bottom of page